Abstract
Islet-Brain (IB) proteins [also called JNK-interacting proteins (JIPs)] are scaffold proteins that are mainly expressed in the pancreatic islets and in the brain. Functionally, the IB family is composed of IB1, IB2, IB3, and IB4 each with distinct splice variants. The IB family of proteins regulates several mitogen-activated protein kinase (MAPK) pathways by tethering their components and modifying the spectrum of substrates targeted by the MAPKs. The expression of these proteins is developmentally regulated, indicating that they play important functions during brain formation. While it is currently unclear what the precise physiological functions of the IB proteins are, there are indications that they participate in subcellular targeting of signalling proteins and modulate cell survival. Synthetic derivatives of these proteins can efficiently counteract apoptotic signalling in cells and tissues and represent therefore promising protective agents against traumatic insults, including stroke and hypoxia. This review will focus on the molecular functions of the IB proteins and their potential implications in the development of several human pathologies.
Keywords: neurodegeneration, alzeihmers disease, apoptosis, mapk, diabetes
Current Neurovascular Research
Title: Islet-Brain (IB)/JNK-Interacting Proteins (JIPs): Future Targets for the Treatment of Neurodegenerative Diseases?
Volume: 1 Issue: 2
Author(s): Nathalie Moulin and Christian Widmann
Affiliation:
Keywords: neurodegeneration, alzeihmers disease, apoptosis, mapk, diabetes
Abstract: Islet-Brain (IB) proteins [also called JNK-interacting proteins (JIPs)] are scaffold proteins that are mainly expressed in the pancreatic islets and in the brain. Functionally, the IB family is composed of IB1, IB2, IB3, and IB4 each with distinct splice variants. The IB family of proteins regulates several mitogen-activated protein kinase (MAPK) pathways by tethering their components and modifying the spectrum of substrates targeted by the MAPKs. The expression of these proteins is developmentally regulated, indicating that they play important functions during brain formation. While it is currently unclear what the precise physiological functions of the IB proteins are, there are indications that they participate in subcellular targeting of signalling proteins and modulate cell survival. Synthetic derivatives of these proteins can efficiently counteract apoptotic signalling in cells and tissues and represent therefore promising protective agents against traumatic insults, including stroke and hypoxia. This review will focus on the molecular functions of the IB proteins and their potential implications in the development of several human pathologies.
Export Options
About this article
Cite this article as:
Moulin Nathalie and Widmann Christian, Islet-Brain (IB)/JNK-Interacting Proteins (JIPs): Future Targets for the Treatment of Neurodegenerative Diseases?, Current Neurovascular Research 2004; 1 (2) . https://dx.doi.org/10.2174/1567202043480161
DOI https://dx.doi.org/10.2174/1567202043480161 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prion Protein Misfolding and Brain Degeneration
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Synthesis of Xanthones and Benzophenones as Inhibitors of Tumor Cell Growth
Letters in Drug Design & Discovery Novel Agents Targeting Bioactive Sphingolipids for the Treatment of Cancer
Current Medicinal Chemistry Transcriptional Regulation of the p53 Tumor Suppressor Gene: A Potential Target for Cancer Therapeutics?
Recent Patents on DNA & Gene Sequences Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Aging and Inflammation: Etiological Culprits of Cancer
Current Aging Science Cyclic AMP Enhancers and Aβ Oligomerization Blockers as Potential Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions
Current Pharmaceutical Biotechnology Adult Neurogenic and Antidepressant Effects of Adiponectin: A Potential Replacement for Exercise
CNS & Neurological Disorders - Drug Targets Subject Index To Volume 7
Current Drug Targets AChE Inhibition-based Multi-target-directed Ligands, a Novel Pharmacological Approach for the Symptomatic and Disease-modifying Therapy of Alzheimer’s Disease
Current Neuropharmacology Development and Clinical Application of Peptide-Based Radiopharmaceuticals
Current Pharmaceutical Design Role of the Insulin Receptor Variant Forms in Human Metabolic Disorders
Current Genomics The Application of Single Nucleotide Polymorphism Microarrays in Cancer Research
Current Genomics Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
Anti-Cancer Agents in Medicinal Chemistry Antimicrobial Sulfated Glycans: Structure and Function
Current Topics in Medicinal Chemistry Proangiogenic Properties of Nucleoside 5'-<i>O</i>-Phosphorothioate Analogues Under Hyperglycaemic Conditions
Current Topics in Medicinal Chemistry An Update on Adenosine A2A-Dopamine D2 Receptor Interactions: Implications for the Function of G Protein-Coupled Receptors
Current Pharmaceutical Design The Intranasal Administration of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP): A New Rodent Model to Test Palliative and Neuroprotective Agents for Parkinsons disease
Current Pharmaceutical Design